CB-109(CB-109) - _专利_临床

概要

基本信息

药物类型

预防性疫苗、mRNA疫苗

别名

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

新型冠状病毒感染

原研机构

Chimeron Bio Corp.初创企业

在研机构-

非在研机构

Chimeron Bio Corp.初创企业

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 CB-109 相关的临床结果

登录后查看更多信息

100 项与 CB-109 相关的转化医学

登录后查看更多信息

100 项与 CB-109 相关的专利（医药）

登录后查看更多信息

1

项与 CB-109 相关的文献（医药）

1992-05-01·European Journal of Cancer1区 · 医学

Establishment and characterisation of a human glioma cell line

1区 · 医学

Article

作者: Catherine Maingonnat ; Marie-Noëlle Courel ; Annie Olivier ; Bertrand Delpech ; Nicole Girard ; Christian Bastard ; Thierry Frébourg ; Pierre Creissard ; Claude Chauzy ; Jean Tayot

A new cell line, CB109, has been established from a human glioblastoma multiforme. The cytoskeleton was positive for glial fibrillary acidic protein, vimentin and fibronectin. Hyaluronan (HA) and the HA-binding protein hyaluronectin (HN) were expressed in the cell cytoplasm and in the extracellular matrix of spheroids and plated cells. Hyaluronidase did not prevent spheroid formation suggesting that HA was not involved in the cell-cell adhesion. HA precoating prevented cell adherence to the plates and favoured spheroid formation. HA was secreted in relatively large amounts into the culture medium. High performance liquid chromatography demonstrated that HA was in the high molecular weight form. The rate of HN secretion by cells was very low. Basic fibroblast growth factor significantly increased the proliferation in vitro and tumour growth after grafting into nude mice. The epidermal growth factor receptor was not expressed on cultivated CB109 cells. Cytogenetic analysis showed polysomy 7, structural rearrangement of chromosome 10 short arm and a translocation 13q13-q14 without detectable alteration of the RB gene.

100 项与 CB-109 相关的药物交易

登录后查看更多信息